Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cyclerion Therapeutics, Inc. - Common Stock
(NQ:
CYCN
)
1.650
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cyclerion Therapeutics, Inc. - Common Stock
FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
January 06, 2026
Via
AB Newswire
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
January 05, 2026
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
September 23, 2025
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
December 17, 2024
Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Regina Graul, Ph.D., Promoted to Chief Executive Officer
August 07, 2024
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Appoints Regina Graul, Ph.D., as President
December 04, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
November 30, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
July 31, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 01, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Reverse Stock Split
May 15, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 11, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
May 11, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 03, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
March 27, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
March 22, 2023
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 22, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 06, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 28, 2022
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 26, 2022
Renowned neuroscience leader to further long-term clinical research strategy and external collaborations
From
Cyclerion Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
